AXGN vs NAGE: fair value comparison
Axogen, Inc. and Niagen Bioscience, Inc. · Updated 2026-10-19
AXGN is still awaiting a full valuation verdict under our six-validated-windows standard. NAGE has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, AXGN currently ranks higher by quality score.
| AXGN | NAGE | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $34.62 | $2.49 |
| 12-month range | $17.77–$51.73 | $2.49–$7.60 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #34 of 301 Healthcare | #35 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Strong | Strong |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: AXGN fair value analysis · NAGE fair value analysis